0001209191-20-004929.txt : 20200124
0001209191-20-004929.hdr.sgml : 20200124
20200124184127
ACCESSION NUMBER: 0001209191-20-004929
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200123
FILED AS OF DATE: 20200124
DATE AS OF CHANGE: 20200124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shawver Laura
CENTRAL INDEX KEY: 0001551891
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38756
FILM NUMBER: 20546756
MAIL ADDRESS:
STREET 1: 1255 CRESCENT GREEN DRIVE, SUITE 250
CITY: CARY
STATE: NC
ZIP: 27518
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Synthorx, Inc.
CENTRAL INDEX KEY: 0001609727
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464709185
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11099 NORTH TORREY PINES ROAD
STREET 2: SUITE 190
CITY: LA JOLLA
STATE: CA
ZIP: 92037
BUSINESS PHONE: (858) 750-4700
MAIL ADDRESS:
STREET 1: 11099 NORTH TORREY PINES ROAD
STREET 2: SUITE 190
CITY: LA JOLLA
STATE: CA
ZIP: 92037
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-23
1
0001609727
Synthorx, Inc.
THOR
0001551891
Shawver Laura
C/O SYNTHORX, INC.
11099 N. TORREY PINES ROAD, SUITE 190
LA JOLLA
CA
92037
1
1
0
0
President and CEO
Common Stock
2020-01-08
4
G
0
80706
0.00
D
215595
D
Common Stock
2020-01-23
4
U
0
220595
68.00
D
0
D
Common Stock
2020-01-23
4
U
0
25000
68.00
D
0
I
By Laura K. Shawver Trust DTD 3/20/2000
Employee Stock Option (right to buy)
0.93
2020-01-23
4
D
0
293177
67.07
D
2028-05-16
Common Stock
293177
0
D
Employee Stock Option (right to buy)
0.63
2020-01-23
4
D
0
172264
67.37
D
2027-12-06
Common Stock
172264
0
D
Employee Stock Option (right to buy)
11.00
2020-01-23
4
D
0
385185
57.00
D
2028-12-05
Common Stock
385185
0
D
Includes 5,000 shares of Common Stock that were acquired by the Reporting Person on January 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan.
This option, which provided for vesting of 27,695 shares on April 12, 2019, with the remaining 363,944 shares vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $19,663,381.39, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
This option, which provided for vesting of 25% of the shares one year after November 27, 2017, with the balance vesting in equal monthly installments thereafter over the next 36 months, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $11,605,425.68, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
This option, which provided for vesting of 33.333% of the shares on December 18, 2019, with 66.667% of the shares subject to the option vesting upon certification by the Compensation Committee of the Board of Directors of the Issuer that the Issuer has received the first approval for commercial sale by a regulatory authority of any product candidate of the Issuer in any territory in the world, was cancelled in connection with the merger of the Issuer with Sanofi's wholly owned subsidiary in exchange for a cash payment of $21,955,545.00, representing the difference between the exercise price of the option and the market value of the underlying common stock of the Issuer on the effective date of the merger ($68).
/s/ Christian V. Kuhlen, Attorney-in-Fact
2020-01-24